CLEC12A, also known as MICL, is inhibitory C-type lectin-like receptor. It contains ITIM motif in cytoplasmic tail that can associate with signaling phosphatases SHP-1 and SHP-2. [6] [7] There are two types, human (hMICL) and murine (mMICL).

人 C 型凝集素样分子 1 （CLL-1），也称为 CLEC12A，是一种 II 型跨膜糖蛋白，作为抑制性受体在免疫调节中发挥重要作用，CLL-1存在于外周血和骨髓的髓系细胞以及大部分AML细胞中，同时表达于多数AML的CD34+CD38-干细胞上，而正常人的CD34+CD38-干细胞不表达，因此CLL-1也是作为治疗AML的潜力靶抗原。 目前，有关CLL-1的药物开发，进入临床阶段的基本上都是CAR-T细胞疗法，且采用多靶点的设计策略，如南京传奇的CLL-1CD33 CART、福建医科大学 …

2025年3月28日 · CLEC12A (C-Type Lectin Domain Family 12 Member A) is a Protein Coding gene. Diseases associated with CLEC12A include 3Mc Syndrome and Mixed Phenotype Acute Leukemia, B/Myeloid . Among its related pathways are Innate Immune System and IL-1 Family Signaling Pathways .

2021年5月27日 · Reduced CLEC12A expression enhances inflammation in CLEC12A knock-out mice with collagen antibody-induced arthritis. Moreover, CLEC12A internalisation augments human neutrophil activation. We...

CLEC12A expression was positively correlated with infiltrating levels of type 2 macrophages and monocytes and negatively associated with NK cells and regulatory T cells in AML. CLEC12A high was positively associated with immune checkpoint …

2025年2月8日 · Mycobacterial mycolic acids trigger inhibitory receptor Clec12A to suppress host immune responses. CLEC12A plays an important role in immunomodulatory function and prognostic significance of patients with acute myeloid leukemia.

CLEC12A是一种重要的细胞表面受体，属于C型凝集素/C型凝集素样域超家族成员。 它具有特定的结构特点，能够与其他分子有效结合并相互作用。 在功能上，CLEC12A参与细胞粘附、信号传导、糖蛋白更新以及免疫和炎症反应等多种生物学过程，同时作为粒细胞和单核细胞功能的负调节因子，参与免疫系统的平衡调节。 在信号通路方面，CLEC12A能够促进靶标MAP激酶蛋白酶的活性，进而在细胞内引发信号转导事件，影响细胞的增殖、分化、凋亡等过程。 此外，它与其 …

2014年3月20日 · The authors found that mouse and human Clec12a recognizes dead cells derived from 293T cells or thymocytes by using Clec12a-immunoglobulin (Ig) fusion protein and reporter cells expressing Clec12a-CD3ζ chimera.

CLEC12A has recently been identified as an antigen, expressed on leukemic stem cells and leukemic blasts. Given the fact that this expression profile seems stable throughout diagnosis, treatment and relapse on leukemic blasts and leukemic stem cells, CLEC12A can be considered a highly potent and rel …

2019年3月1日 · Low CLEC12A expression on leukemic blasts seems to be independently associated with lower likelihood of achieving complete remission after 1 cycle of induction chemotherapy, shorter event free survival, as well as overall survival, indicating potential prognostic properties of CLEC12A expression itself.